Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alembic PharmaceuticalsBOM:533573 +0.31%75 Pretax Margin % is 6.42% as of Mar. 2026, which is 56% below its 10-year median of 14.71. GuruFocus rates BOM:533573 with a GF Score™ of 75/100 and a GF Value™ of ₹1,054.49 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Alembic Pharmaceuticals ranks better than 56.83% on this metric.
The historical rank and industry rank for Alembic Pharmaceuticals's Pretax Margin % or its related term are showing as below:
BOM:533573'
s Pretax Margin % Range Over the Past 10 Years
Min: 6.45 Med: 14.71 Max: 25.93
Current: 9.45
BOM:533573's Pretax Margin % is ranked better than 56.83% of 959
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs BOM:533573: 9.45
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Alembic Pharmaceuticals Pretax Margin % Related Terms
Alembic Pharmaceuticals Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:533573 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alembic Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alembic Pharmaceuticals Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alembic Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Alembic Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alembic Pharmaceuticals (BOM:533573) has a Pretax Margin % of 6.42% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Alembic Pharmaceuticals and its competitors. This is 56% below median its historical median of 14.71. Over the past decade, Alembic Pharmaceuticals' Pretax Margin % has ranged from 6.45 to 25.93. According to the industry distribution chart, Alembic Pharmaceuticals ranks #414 out of 959 companies in the Drug Manufacturers industry, placing it in the top 43.2%.
Is Alembic Pharmaceuticals' Pretax Margin % too high?
Alembic Pharmaceuticals' current Pretax Margin % of 6.42% is 56% below median its 10-year median of 14.71. Over the past 10 years, this metric has ranged from a low of 6.45 to a high of 25.93. The Drug Manufacturers industry median Pretax Margin % is 7.28. Alembic Pharmaceuticals' value of 6.42% is 11.8% below this industry median. Based on the distribution chart, Alembic Pharmaceuticals ranks #414 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Alembic Pharmaceuticals has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alembic Pharmaceuticals' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alembic Pharmaceuticals ranks #414 out of 959 companies for Pretax Margin %. This puts Alembic Pharmaceuticals in the upper half of its industry. The industry median Pretax Margin % is 7.28. Alembic Pharmaceuticals' value of 6.42% is 11.8% below this benchmark. Historically, Alembic Pharmaceuticals' own Pretax Margin % has ranged from 6.45 to 25.93 over the past decade. While the company's 10-year median is 14.71 vs. the industry median of 7.28, Alembic Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alembic Pharmaceuticals's current Pretax Margin % of 6.42% is 11.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Alembic Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alembic Pharmaceuticals's current Pretax Margin % is 6.42%, which is 56% below median its own 10-year median of 14.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alembic Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alembic Pharmaceuticals (BOM:533573) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,054.49, compared to a current price of ₹796.50 — trading 24.5% below its estimated fair value. The current Pretax Margin % is 6.42%, which is 56% below median its 10-year median of 14.71 and 11.8% below the Drug Manufacturers industry median of 7.28. Alembic Pharmaceuticals' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Alembic Pharmaceuticals (BOM:533573), the current Pretax Margin % is 6.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alembic Pharmaceuticals (BOM:533573) Overvalued in 2026?
Based on GuruFocus' analysis, Alembic Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹796.50 is trading 24.5% below its estimated GF Value™ of ₹1,054.49.
GuruFocus considers Alembic Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BOM:533573:
Pretax Margin %: 6.42% (56% below median its 10-year median of 14.71)
GF Value™: ₹1,054.49 vs. price of ₹796.50 (24.5% below fair value)
Industry Position: 11.8% below the Drug Manufacturers median (#414 of 959)
No single metric tells the full story. See the BOM:533573 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities.
75GF Score
Get the complete analysis for BOM:533573
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:533573 has been successfully added to your 
